trending Market Intelligence /marketintelligence/en/news-insights/trending/68-TZIMGsDEH05keH6MTIA2 content esgSubNav
In This List

Actelion shareholders approve spinoff of R&D unit

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Actelion shareholders approve spinoff of R&D unit

Actelion Ltd. shareholders approved the spinoff of its drug discovery and early clinical pipeline at its April 5 annual general meeting.

The spinoff is part of Johnson & Johnson's acquisition of Actelion, which is on track to close in the second quarter of 2017.

The spinoff company, Idorsia, will be led by Actelion founder Jean-Paul Clozel as CEO, and Actelion Chairman Jean-Pierre Garnier as chairman.

Johnson & Johnson recently completed the main tender offer for the Actelion acquisition.